I share my unique aggressive treatment journey over 11 years, highlighting a common hope for more time and better treatments.

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

Bangalore-based biotech startup Mestastop Solutions has been awarded the Best Metastasis R&D Specialist for 2025 by the ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

“But One Day to Remember makes sure they get to experience joy - even in the most challenging times.” And despite a terminal ...

During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with ...

Cell crowding causes high-grade breast cancer cells to become more invasive by activating a molecular switch that causes the cells to shrink and spread.

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...

A new study finds that fragments of tumor DNA in a patient's bloodstream could show that they are at high risk of a melanoma ...

Researchers from Tokyo Metropolitan University have found that the motion of unlabeled cells can be used to tell whether they ...

A new report on cancer in the US shows a steady decline in overall deaths from 2001 through 2022. The rate of diagnoses among ...